5/15/2025

Janusmed sex and gender

Janusmed sex and gender – Sunitinib

Janusmed Sex and Gender is a knowledge database providing information on sex and gender aspects of drug treatment. The knowledge database is primarily intended to be used by physicians and healthcare professionals. The texts are general and should not be considered as treatment guidelines. The individual patient’s physician is responsible for the patient’s drug treatment.

Back to index
C! C!
C! C!

Sunitinib

Sunitinib

Class : C!

Show all info

Print

Contact us

  1. SUTENT (sunitinib). EPAR - Product information. European Medicines Agency (EMA) [updated 2024-03-06, cited 2025-03-13]

  2. Vera Regitz-Zagrosek. Sex and Gender Differences in Pharmacology. Springer-Verlag Berlin Heidelberg; 2012.

  3. Khosravan R, Motzer RJ, Fumagalli E, Rini BI. Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor. Clin Pharmacokinet. 2016;55(10):1251-1269.

  4. Houk BE, Bello CL, Kang D, Amantea M. A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clin Cancer Res. 2009;15(7):2497-506.

  5. Segarra I, Modamio P, Fernández C, Mariño EL. Sunitinib Possible Sex-Divergent Therapeutic Outcomes. Clin Drug Investig. 2016;36(10):791-9.

  6. van der Veldt AA, Boven E, Helgason HH, van Wouwe M, Berkhof J, de Gast G et al. Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. Br J Cancer. 2008;99(2):259-65.

  7. Akaza H, Naito S, Ueno N, Aoki K, Houzawa H, Pitman Lowenthal S et al. Real-world use of sunitinib in Japanese patients with advanced renal cell carcinoma: efficacy, safety and biomarker analyses in 1689 consecutive patients. Jpn J Clin Oncol. 2015;45(6):576-83.

  8. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2024 [cited 2025-04-23.]

  1. SUTENT (sunitinib). EPAR - Product information. European Medicines Agency (EMA) [updated 2024-03-06, cited 2025-03-13]
  2. Vera Regitz-Zagrosek. Sex and Gender Differences in Pharmacology. Springer-Verlag Berlin Heidelberg; 2012.
  3. Khosravan R, Motzer RJ, Fumagalli E, Rini BI. Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor. Clin Pharmacokinet. 2016;55(10):1251-1269.
  4. Houk BE, Bello CL, Kang D, Amantea M. A population pharmacokinetic meta-analysis of sunitinib malate (SU11248) and its primary metabolite (SU12662) in healthy volunteers and oncology patients. Clin Cancer Res. 2009;15(7):2497-506.
  5. Segarra I, Modamio P, Fernández C, Mariño EL. Sunitinib Possible Sex-Divergent Therapeutic Outcomes. Clin Drug Investig. 2016;36(10):791-9.
  6. van der Veldt AA, Boven E, Helgason HH, van Wouwe M, Berkhof J, de Gast G et al. Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer. Br J Cancer. 2008;99(2):259-65.
  7. Akaza H, Naito S, Ueno N, Aoki K, Houzawa H, Pitman Lowenthal S et al. Real-world use of sunitinib in Japanese patients with advanced renal cell carcinoma: efficacy, safety and biomarker analyses in 1689 consecutive patients. Jpn J Clin Oncol. 2015;45(6):576-83.
  8. Statistikdatabas för läkemedel. Stockholm: Socialstyrelsen. 2024 [cited 2025-04-23.]